At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
Pazopanib Hydrochloridedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Efficacy Trial of Pazopanib in Non-clear Cell Metastatic Renal Cell Cancer (mRCC) PINCR
In Brief
A Phase 2 clinical trial evaluating Pazopanib Hydrochloride for Carcinoma of the Collecting Ducts of Bellini and 8 related conditions. Completed, enrolled 38 participants across 3 sites.
Detailed Summary
This phase II trial studies how well pazopanib hydrochloride works in treating patients with kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of kidney cancer by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma, Kidney Medullary Carcinoma, Kidney Oncocytoma, Metastatic Renal Cell Cancer, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartMay 2013
Primary CompletionFeb 2019
Study CompletionJan 2021
TodayJul 2026
First PostedJan 14, 2013
Enrollment StartMay 16, 2013
Primary CompletionFeb 2, 2019
Study CompletionJan 20, 2021
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 13.5 years ago
Interventions
Pazopanib Hydrochloridedrug
Given PO